PDF(Pubmed)
Abstract：
UNASSIGNED: Dry Eye Disease (DED) is a multifactorial chronic inflammatory condition of the corneal surface, attributed to insufficient or low-quality production of tears, accounting for 5-50% of the cases globally. Artificial tears are the first line of treatment as they reduce ocular surface tension, and improve film stability and optical quality. EzriCare Artificial Tears are preservative-free, multi-dose, readily accessible eye drops containing carboxymethylcellulose sodium solution (10 mg in 1 ml) aiming for relief against DED. This article discusses the public health challenges faced by the use of EzriCare Artificial Tears and emphasizes the need for alternative therapies for the effective management of DED.
UNASSIGNED: We searched for articles documenting the incidence of the current multi-drug resistant P. aeruginosa strain outbreak caused by the use of preservative-free artificial tears and the challenges faced through the use of artificial tears on PubMed, and Google Scholar.
UNASSIGNED: EzriCare and other preservative-free artificial tears have been reported to pose a serious public health risk as they have been found to be the commonly used product among the people infected with the current multi-state outbreak of the multi-drug resistant P. aeruginosa strain.
UNASSIGNED: The current multi-state outbreak of the multi-drug resistant P. aeruginosa strain has raised concerns about the safe use of other artificial products. It is high time that further trials should be conducted on other alternative strategies and evaluate the safety and efficacy of nanotechnology in the treatment of dry eye disease.
UNASSIGNED: We searched for articles documenting the incidence of the current multi-drug resistant P. aeruginosa strain outbreak caused by the use of preservative-free artificial tears and the challenges faced through the use of artificial tears on PubMed, and Google Scholar.
UNASSIGNED: EzriCare and other preservative-free artificial tears have been reported to pose a serious public health risk as they have been found to be the commonly used product among the people infected with the current multi-state outbreak of the multi-drug resistant P. aeruginosa strain.
UNASSIGNED: The current multi-state outbreak of the multi-drug resistant P. aeruginosa strain has raised concerns about the safe use of other artificial products. It is high time that further trials should be conducted on other alternative strategies and evaluate the safety and efficacy of nanotechnology in the treatment of dry eye disease.
摘要：
■干眼病（DED）是角膜表面的多因素慢性炎症，归因于眼泪产量不足或低质量，占全球病例的5-50%。人工泪液是治疗的第一线，因为它们降低了眼表面张力，提高薄膜稳定性和光学质量。EzriCare人造眼泪不含防腐剂，多剂量,容易获得的含有羧甲基纤维素钠溶液（10毫克，1毫升）的滴眼液旨在缓解DED。本文讨论了使用EzriCare人工泪液所面临的公共卫生挑战，并强调需要替代疗法来有效管理DED。
■我们搜索了一些文章，这些文章记录了由于使用不含防腐剂的人工泪液而导致的当前多重耐药铜绿假单胞菌爆发的发生率，以及在PubMed上使用人工泪液所面临的挑战，谷歌学者。
■据报道，EzriCare和其他不含防腐剂的人工泪液构成严重的公共卫生风险，因为它们已被发现是当前多州感染的人群中常用的产品。多重耐药铜绿假单胞菌菌株的爆发。
■当前多药耐药铜绿假单胞菌菌株的多州爆发引起了人们对其他人造产品安全使用的担忧。现在是时候对其他替代策略进行进一步试验，并评估纳米技术治疗干眼病的安全性和有效性。
■我们搜索了一些文章，这些文章记录了由于使用不含防腐剂的人工泪液而导致的当前多重耐药铜绿假单胞菌爆发的发生率，以及在PubMed上使用人工泪液所面临的挑战，谷歌学者。
■据报道，EzriCare和其他不含防腐剂的人工泪液构成严重的公共卫生风险，因为它们已被发现是当前多州感染的人群中常用的产品。多重耐药铜绿假单胞菌菌株的爆发。
■当前多药耐药铜绿假单胞菌菌株的多州爆发引起了人们对其他人造产品安全使用的担忧。现在是时候对其他替代策略进行进一步试验，并评估纳米技术治疗干眼病的安全性和有效性。
